NRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 million

Reuters2026/08/14 20:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NRX Pharmaceuticals posted a GAAP net loss of USD 16.52 million for the quarter ended June 30, 2026, narrowing from USD 17.58 million.
Revenue was USD 1.1 million, versus no revenue a year earlier, reflecting patient services from Dura acquired in September 2025.
Operating loss widened to USD 6.51 million from USD 3.73 million as total operating expense climbed to USD 7.61 million from USD 3.73 million.
Other expense fell to USD 10.02 million from USD 13.85 million as losses tied to convertible notes and note conversions dropped to none.
Cash rose to USD 26.69 million at June 30, 2026 from USD 7.8 million at December 31, 2025, following USD 20.7 million net offering proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028027), on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

NRx Pharma Q2 FY26 net loss narrows to $16.52 million; revenue rises to $1.1 million

You may also like

Crypto prices